4 Reasons to Buy Amgen Stock Right Now
Major market indexes such as the S 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant (NASDAQ: AMGN) started the year strong, but has not maintained that momentum. Over the past six months, Amgen's shares have declined by 9%. The drugmaker is facing some issues, including upcoming patent cliffs.
Even so, there remain strong reasons to invest in Amgen and hold on to its shares for the long haul. Let's consider four of them.
Amgen lost patent protection for Prolia, a medicine for bone health, earlier this year. In the next few years, it will encounter other patent cliffs, including that of the cancer drug Krypolis and the immunosuppressant Otezla. The loss of exclusivity for these therapies will impact top-line growth, but as every drugmaker knows, the best way to overcome this challenge is to develop newer drugs.
Source Fool.com
Amgen Inc. Aktie
Und Amgen Inc. steht derzeit mit 26 Buy-Einschätzungen und 4 Sell-Einschätzungen bei unserer Community gut im Kurs.
Ein Kursziel von 296 € für Amgen Inc. impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 270.75 €.
